BIO-BRIDGE TO DEVELOP HPV VACCINE IN CHINA

Bio-Bridge Science announced it has entered into a cooperative agreement with the Chinese Academy of Medical Sciences to research and develop a human papillomavirus (HPV) polyvalent vaccine using a prokaryotic expression system.

The vaccine is designed to prevent infection with HPV types 6, 11, 16, 18, 31, 45 and 58 and is expected to provide broader protection than the current vaccine and have much lower production costs, the company said. Under the agreement, Bio-Bridge has been granted the preferential right to develop the vaccine and enjoys a 60 percent interest in the project.

"We believe that our agreement with the Chinese Academy of Medical Sciences will enable us to solidify our research capability in China as we try to introduce more potential vaccine products in addition to our current vaccine pipeline," Liang Qiao, chairman and CEO of Bio-Bridge, said.